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ABSTRACT
Background: Treatment guidelines recommend the use of inhaled corticosteroids (ICS) as first-line therapy
for all stages of persistent asthma. However, it is unknown whether ICS dose reduction in adult asthmatics is
compatible with maintaining asthma control. Moreover, there are no predictors of efficacy in maintaining
asthma control upon ICS reduction.
Methods: We recruited 90 adult patients with moderate or severe asthma but no clinical symptoms of asthma
for at least 6 months. All patients reduced their ICS doses by half but continued taking other asthma-related
medications. As a primary outcome, we measured asthma exacerbations during the 12 months following ICS
reduction. We also further monitored patients from the above study who had maintained total asthma control for
12 months after ICS reduction and who had continued on their reduced doses of ICS or had further reduced, or
stopped, their ICS.
Results: Forty of ninety patients (44.4%) experienced exacerbations after ICS reduction (time to first exacer-
bation: 6.4 ± 3.6 months). Multivariate logistic regression modeling revealed a rank order of predictors of suc-
cess in ICS reduction while retaining asthma control: acetylcholine (ACh) PC20 (p < 0.01); length of time with no
clinical symptoms before ICS reduction (p < 0.01); FeNO (p = 0.028); and forced expiratory volume in 1 s
(FEV1; % predicted) (p = 0.03). Finally thirty-nine of 50 patients maintained total asthma control for at least 2
years after the initial ICS reduction.
Conclusions: In asthma patients with normalized AChPC20 of 20 mgmL or 10 mgmL and no clinical symp-
toms for at least 12 or 24 months it may be possible to successfully reduce ICS without increasing exacerba-
tions for long time.
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INTRODUCTION
Treatment guidelines recommend the use of inhaled
corticosteroids (ICS) as first-line therapy for persis-
tent asthma of all severities.1 Controlled asthma is de-
fined by the Global Initiative for Asthma (GINA)
guidelines as no daytime symptoms or limitation of
activities, no nocturnal symptoms or awakening, no
need for reliever or rescue treatment, and normal
lung function (peak expiratory flow or forced expira-
tory volume in 1 s (FEV1) > 80% of predicted or per-
sonal best). GINA guidelines recommend that, when
control is maintained for at least 3 months, treatment
can be stepped down to minimize cost and maximize
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the safety of the treatment. For asthma control
achieved by medium-to-high daily doses of ICS alone,
a 50% reduction in daily dose should be attempted af-
ter 3 months of control.2-4 For control achieved by
low-dose ICS alone, most patients may be switched to
once-daily dosing.5,6 For asthma controlled with the
combination of ICS and a long-acting β2-agonist
(LABA), the preferred approach is to reduce the daily
dose of ICS by approximately 50% while continuing
the LABA.7 Discontinuing LABA too early in con-
trolled asthma in patients treated with ICS and LABA
leads to loss of asthma control.8-10
It has been reported that asthma management can
be achieved by combining increased or decreased in-
haled ICS with a short-acting β2-agonist11 and by
monitoring FeNO,12-14 induced-sputum eosinophil
count,14-17 bronchial hyperresponsiveness (BHR),15
or the morbidity score2 (which includes asthma clini-
cal symptoms). However, these studies8-10,12,15,16,18-20
monitored clinical outcomes only from 1 to 6 months
after ICS reduction. The prognosis remains unknown
for patients more than 1 year after stepping down
their daily ICS dose. In fact, there are reports that re-
duction of ICS leads to a deterioration in asthma con-
trol in adult patients.2,10,16,18 Moreover, predictive fac-
tors that can be evaluated at the time of ICS reduc-
tion, or before the initiation of any asthma treatment,
are unknown. Predictors might include clinical symp-
toms, lung function, airway responsiveness, or
biomarkers such as eosinophilic inflammation in the
airways.
We previously reported that 47 of 134 adult pa-
tients with asthma (35.1%) who did not have symp-
toms in the 6 months after achieving normalized BHR
to acetylcholine (ACh) experienced exacerbations at
a mean of 8.0 ± 7.0 months after their daily doses of
ICSs were halved.21 Here, to identify predictors of
success in decreasing inhaled ICS without increasing
exacerbations in the subsequent 12 months, we
prospectively studied adult asthma patients in whom
ICS intake was reduced.
METHODS
PATIENTS
Between March 2009 and May 2010, we recruited 90
adult patients at the Clinical Research Center for Al-
lergy and Rheumatology, National Hospital Organiza-
tion, Sagamihara, Kanagawa, Japan, who suffered
from moderate or severe asthma and who had not
had any clinical symptoms of asthma for at least 6
months. All patients had been diagnosed according to
the American Thoracic Society criteria.22 Asthma se-
verity was assessed according the current GINA
guidelines1 and classified according to those guide-
lines as: Step 1, intermittent; Step 2, mild persistent;
Step 3, moderate persistent; and Step 4, severe per-
sistent. Exclusion criteria included pulmonary dis-
eases other than asthma (chronic obstructive pulmo-
nary disease, interstitial pulmonary fibrosis, and
bronchial ectasis) and eosinophilic lung diseases
such as allergic bronchopulmonary mycosis and
Churg-Strauss syndrome.
STUDY DESIGN
STUDY 1: All recruited patients were receiving ICS
therapy but had not had any clinical symptoms for at
least 6 months while on therapy. We confirmed that
all patients were free of clinical symptoms and had
been for at least 6 months by medical examination
and review of diaries in which they had recorded
their symptoms. Monitored symptoms included day-
time symptoms such as a wheeze and expiratory
dyspnea, night-time awakenings due to asthma or use
of rescue metered-dose inhalers, and emergency
room visits due to exacerbations. All patients had
their daily ICS doses halved but remained on the
same ICS with no change in particle size or device.
However, patients continued taking other medica-
tions such as theophylline, long-acting β-agonists, leu-
kotriene receptor antagonists (LTRA), andor anti-
cholinergic agents. We prospectively studied all pa-
tients during the 12 months following the ICS reduc-
tion by reviewing symptoms they recorded in a diary
and by medical examinations every 2 or 3 months.
The primary outcome measure was clinical symp-
toms. An asthma exacerbation was defined as the oc-
currence of symptoms more than once a week or a
need by the patient to use inhaled short acting β-
agonists more than twice a month. Symptoms were
defined as wheezing and expiratory dyspnea during
the day or night-time awakenings due to asthma.21 If
necessary, patients that experienced an exacerbation
were placed back on the daily dose of ICS that they
had been using before the start of the study and
treated with short-term systemic corticosteroids or
long- or short-acting β-agonists. Not all patients that
experienced exacerbations required hospitalization
for an asthma attack.
STUDY 2: We further monitored for another 12
months the prognosis of patients for another 12
months in Study 1 who had maintained total asthma
control for 12 months after ICS reduction. These pa-
tients were distributed into three groups: 1) patients
who continued their halved initial daily ICS dose; 2)
patients with severe asthma whose daily ICS dose be-
fore the dose halving had been the maximum (1600
μg as chlorofluorocarbon beclometasone dipropion-
ate; CFC-BDP equivalent) and whose daily ICS dose
after 12 months was decreased to one-quarter of the
initial daily dose; and 3) patients with moderate
asthma who, after 12 months, discontinued their
halved ICS dose (400 μg CFC-BDP equivalent) com-
pletely (Fig. 1).
At the first hospital visit, and before ICS treatment,
eosinophils in non-induced sputum were quantified
by using the Hansel classification system.23 The pro-
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Fig.　1　Protocol and follow-up for patients studied for an additional 12 months after 12 months of reduced daily 
ICS. Fifty patients who were exacerbation-free 12 months after ICS reduction were distributed into three groups 
(21 patients continued their daily ICS half-dose, 18 reduced their daily ICS dose to a quarter of the original dose, 
and 11 discontinued their reduced ICS dose of 400 μg).
Adult patients with asthma who had had no clinical symptoms of asthma for at least 6 months.
All patients reduced their daily ICS doses by half.
40 patients with exacerbation 
within 12 months
50 patients without exacerbation within 12 months
21 patients continued their
daily ICS half-dose.
18 patients reduced their
daily ICS dose to a quarter
their original dose.
11 patients discontinued
all ICS doses.
Follow up for another 12 months
Exacerbations:
1 of 21
Exacerbations:
4 of 18
Exacerbations:
6 of 11
Fig.　2　Clinical courses of patients after ICS reduction. Kaplan-Meier plot of the 
percentage of patients remaining free of exacerbations. Patients were free of clini-
cal symptoms for at least 6 months before entering the study.
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Fig.　3　Time until initial exacerbation. Numbers of patients and times af-
ter ICS reduction at which they experienced an initial exacerbation.
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portion of eosinophils in whole blood was also meas-
ured. Eosinophil amounts in sputum were scored by
microscopy as 0 (none), 1 (few; 1 in 1 microscope
field), 2 (slight; small numbers in 1 field), 3 (mild;
moderate numbers in 1 field), 4 (moderate; many in 1
field), or 5 (severe; many in all fields), with scores of
0 and 1 consistent throughout the entire smear and
scores of 2 to 5 verified under high power (400×).
Antigen sensitivity was measured by intracutane-
ous skin testing.24 In brief, a 0.05-mL solution of each
of six allergens (house dust mite, cat, dog, Alternaria
tenuis, Aspergillus fumigatus, and ragweed) was in-
jected intradermally and the effect judged 15 min af-
ter injection. Histamine (0.4 μg) was used as a posi-
tive control. Skin reactions were judged positive if
they were larger than the histamine reaction. Atopy
was defined as a positive intracutaneous skin reaction
to at least one antigen.
FeNO was measured (see below) when the daily
dose of ICS was reduced. Provocation tests with ACh
or histamine (Hist) were performed (see below) on
separate days within 1 month after the first hospital
visit and at the time of reduction of inhaled ICS. All
patients were treated with anti-asthma drugs such as
short-acting β2 agonists or sustained-release theo-
phylline before ICS treatment within one month from
the first visit.
The hospital ethics committee approved the study
in accordance with the Helsinki Declaration. We ob-
tained written informed consent from each patient.
MEASUREMENT OF BRONCHIAL HYPERRE-
SPONSIVENESS TO ACH AND HIST
We performed inhalation testing using a modified
method according to American Thoracic Society
(ATS) guidelines.25 All anti-asthma medications were
withheld for at least 12 h before the provocation test.
We prepared ACh chloride (Ovisot, Daiichi Pharma-
ceutical, Tokyo, Japan) at 0.157, 0.316, 0.625, 1.25,
2.5, 5, 10, and 20 mgmL and Hist dihydrochloride
(Sigma, St Louis, MO, USA) at 0.078, 0.157, 0.316,
0.625, 1.25, 2.5, 5, and 10 mgmL by dilution in buff-
ered saline solution (pH 7.4). FEV1 was measured
with a spirometer (Auto Spiro AS-303, Minato Medi-
cal Science, Osaka, Japan) after each inhalation. Sub-
jects inhaled ACh aerosol from a nebulizer (DeVilbiss
646, DeVilbiss, Somerset, PA, USA) by tidal breath-
ing for 2 min. The operating airflow of this device was
5 Lmin. Isotonic saline was inhaled first as a control.
Patients with FEV1 <1.00 L or showing a decrease of
>10% with saline alone were not tested further. In-
creasing concentrations of ACh or Hist were then in-
haled until FEV1 fell by >20% of its post-saline value or
until the maximum ACh or Hist concentration was
reached. The percentage fall in the FEV1 from the
post-saline solution value was plotted against the log
concentration of inhaled ACh or Hist. Bronchial sen-
sitivity is expressed as the provocative concentration
of the agonist causing a decrease in FEV1 of >20%
(PC20). At the end of the test, any fall in the FEV1 was
reversed by the inhalation of salbutamol (0.5 mL of a
5 mgmL solution). Subjects with an AChPC20 of <20
mgmL or a HistPC20 of <10 mgmL were defined as
having positive BHR.
MEASUREMENT OF FeNO
Exhaled air was collected with a Sievers bag collec-
tion kit in accordance with the method reported by
Tsuburai et al.26 Briefly, subjects took a deep breath
of room air through the NO scavenging filter and ex-
haled through a mouthpiece with a flow rate of 70
mLs against an expiratory resistance of 10 cm H2O;
5 s later, the exhaled air was collected into the 1.5-L
Mylar bag provided in the kit. The collected exhaled
Step-Down of ICS in Adult Asthma
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Table　1　Baseline factors for patients who were exacerbation-free, or not, in the 12 months following ICS reduction
Exacerbation-free
group N = 50
Exacerbation
group N = 40 p-value
Age at entry of study (y)†  49.1 ± 14.6  50.9 ± 15.9 NS1
Sex (M/F) 17/33 15/25 NS3
Age at onset of asthma (y)†  34.7 ± 18.0  35.8 ± 20.7 NS1
Age at fi rst hospital visit (y)†  41.1 ± 14.7  43.9 ± 15.7 NS1
Duration of asthma (from age at onset to entry )†  14.5 ± 10.5  15.2 ± 12.8 NS1
Type: atopy/nonatopy 37/13 24/16 NS3
Smoking history (non-smoker/ex-smoker + current smoker) 36/14 28/12 NS3
At fi rst hospital visit
Number with step 1/2/3/4 asthma severity‡ 0/0/25/25 0/0/18/22 NS3
log IgE RIST in serum†  2.343 ± 0.579  2.325 ± 0.749 NS2
Patients with eosinophils (%) in WBC  6.3 ± 4.3  7.0 ± 5.4 NS1
Eosinophil score in sputum§ (score ≤2, ≥3) 17/13 12/12 NS3
VC (predicted, %)† 103.4 ± 17.4 101.0 ± 16.3 NS1
FEV1 (predicted, %)†  85.9 ± 20.8  79.6 ± 21.3 NS1
V50 (predicted, %)†  57.9 ± 28.5  55.5 ± 29.1 NS1
V25 (predicted, %)†  50.8 ± 40.1  41.5 ± 23.5 NS3
Mean AChPC20 (range)(μg/mL) 4852.9 (322-20000) 4508.2 (430-20000) NS3
Mean HistPC20 (range) (μg/mL) 1056.8 (141-10000) 946.2 (67-10000) NS3
At ICS reduction
FEV1 (predicted, %)†  91.1 ± 15.1  84.1 ± 16.7 <0.051
V50 (predicted, %)†  74.3 ± 26.3  68.1 ± 25.9 NS1
V25 (predicted, %)†  67.5 ± 24.0  59.9 ± 25.7 NS1
Mean AChPC20 (range)(μg/mL) 17823.8 (6422-20000)  9616.1 (1088-20000) <0.013
Mean HistPC20 (range) (μg/mL) 4375.2 (472-10000) 2157.7 (138-10000) <0.053
FeNO (ppb) in all patients†  25.6 ± 12.0  43.4 ± 27.3 <0.013
FeNO (ppb) in non-smoking patients†  25.1 ± 12.5  41.4 ± 27.0 <0.013
FeNO (ppb) in ex- or current- smoking patients†  26.7 ± 11.2  47.6 ± 28.8 <0.013
Duration with no clinical symptoms (months)† 15.2 ± 9.4 11.1 ± 6.9 <0.053
†Mean ± standard deviation.
‡According to GINA guidelines.
§According to the Hansel classifi cation.
NS, not signifi cant.
1Two-way ANOVA with repeated measures among two groups.
2Differences between groups were evaluated by using the Mann-Whitney U-test.
3Chi-squared testing revealed no signifi cant differences in the values for the two groups.
Values of p < 0.05 were considered statistically signifi cant.
air was stored at room temperature and the NO con-
centration measured within 12 h. The air was drawn
out of the balloons at 200 mLmin into an NO chemi-
luminescence analyzer (NOA model 280A, Sievers In-
struments) with a response time of 200 ms. The
FeNO measured by this method is consistent with
about 80% of the values measured with online meth-
ods.26
STATISTICAL ANALYSIS
All values are expressed as means ± standard devia-
tion (range) unless otherwise specified. Statistical
comparisons between groups were performed by
means of a two-way analysis of variance (ANOVA)
with repeated measures or with the Mann-Whitney U-
test. A multiple logistic regression analysis was used
to calculate risk factor coefficients. Values of p < 0.05
were considered statistically significant. Statistical
analysis was performed with StatView v. 5.0 software
(SAS Institute; Cary, NC, USA).
RESULTS
STUDY 1: Forty of ninety asthma patients (44.4%)
given reduced ICS daily doses experienced asthma
exacerbations during the study. The mean time to the
first exacerbation was 6.4 ± 3.6 months (Fig. 2).
Twenty-three of the forty patients (57.5%) experi-
enced exacerbations sooner than 6 months. The re-
Tsurikisawa N et al.
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Table　2　Treatment characteristics before ICS reduction
Exacerbation-free
group N = 50
Exacerbation
group N = 40 p-value
ICS therapy until reduction
Duration from onset of asthma to initiation of ICS therapy (y)†  7.1 ± 8.0   9.1 ± 11.4 NS1
Type of ICS; FP/BUD/BDP-HFA/CIC 22/25/2/1 19/13/7/1 NS2
Daily dose of ICS (μg) (converted to CFC-BDP equivalent)† 1172.0 ± 423.8 1130.0 ± 421.4 NS1
Duration of ICS therapy (y)†  2.5 ± 2.0  2.3 ± 1.7 NS1
At ICS reduction
Use of LABA; n (%) 16 (32.0%) 15 (37.5%) NS2
Use of LTRA; n (%)  7 (14.0%)  7 (17.5%) NS2
Use of LAMA; n (%)  3 ( 6.0%)  2 ( 5.0%) NS2
Use of theophylline; n (%)  2 ( 4.0%)  5 (12.5%) NS2
†Mean ± standard deviation.
NS, not signifi cant; FP, fl uticasone propionate; BUD, budesonide; BDP-HFA, beclometasone dipropionate hydrofl uoroalkanes; CIC, cicle-
sonide; LABA, long-acting b agonist; LTRA, leukotriene receptor antagonist; LAMA, long-acting muscarine antagonist.
1Two-way ANOVA with repeated measures among two groups.
2Chi-squared testing revealed no signifi cant differences in the frequencies of two groups.
Values of p < 0.05 were considered statistically signifi cant.
Fig.　4　Season at ICS reduction. Numbers of patients and seasons at the time of 
ICS reduction. Spring represents March through May, summer June through Au-
gust, autumn September through November, and winter December through Febru-
ary. Black bars indicate patients with exacerbations. White bars indicate patients 
without exacerbations.
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maining patients that experienced exacerbations
(42.5%) experienced their first one between 6 and 12
months after their ICS reductions (Fig. 3).
All patients were classified as step 3 or 4 on the ba-
sis of the GINA guidelines. For comparison, the pa-
tients were grouped into those that had experienced
an exacerbation and those that had not (Table 1).
There were no significant differences between the pa-
tient groups in terms of age at entry into the study,
sex ratio, age of onset of asthma, duration of asthma,
atopy status, or smoking history. Nor were there sig-
nificant differences between the two groups in terms
of serum IgE level, as measured by using the Radio-
ImmunoSorbent Test (RIST), eosinophils as a per-
centage of WBCs, score of eosinophils in sputum,
%VC, FEV1%, %V50, %25, AChPC20, or HistPC20 at
the first hospital visit. However, upon reduction of in-
haled ICS, the group without exacerbations had sig-
nificantly higher %FEV1 (p < 0.05), AChPC20 (p <
0.01), and HistPC20 (p < 0.05) and the duration of the
period without clinical symptoms was significantly
longer (p < 0.05). In addition, for all patients and for
patients grouped as non-smokers or ex- and current-
smokers, FeNO was significantly lower in the
exacerbation-free group than in the group with exac-
erbations (Table 1). There was no effect of the season
at ICS reduction on the number of patients with or
without exacerbations (Fig. 4). The number of
months with no clinical symptoms following ICS re-
duction was 15.2 ± 9.4 for patients without, and 11.1 ±
Step-Down of ICS in Adult Asthma
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Table　3　Logistic regression modeling of baseline factors predictive of the success of ICS reduction
Variable Exponent 95% confi dence interval p-value
Age at asthma onset 0.994 0.946-1.044 0.81
Duration of asthma (from age at onset to entry) 0.987 0.906-1.074 0.75
Type: atopic/nonatopic 0.254 0.062-1.037 0.056
Smoking history (non-smoker/ex- + current smoker) 0.435 0.103-1.833 0.26
ICS therapy until ICS reduction
Daily dose of ICS 0.999 0.998-1.001 0.40
At ICS reduction
FEV1 1.104 1.009-1.207 0.03*
V50 0.956 0.912-1.003 0.068
AChPC20 35.1 4.073-30.184 <0.01**
HistPC20 2.474 0.466-13.141 0.29
FeNO 0.961 0.927-0.996 0.028*
Length of time with no clinical symptoms before ICS reduction 1.182 1.056-1.323 <0.01**
*p < 0.05 by logistic regression, **p < 0.01 by logistic regression.
Table　4　Patient characteristics at time of ICS reduction, and percentages of patients with no exacerbations for 1 year after re-
duction
Characteristics at time of ICS reduction % with no exacerbations for1 year
AChPC20 >20 mg/mL 75.00
AChPC20 >20 mg/mL + time with no clinical symptoms before ICS reduction ≥12 months 86.20
AChPC20 >20 mg/mL + time with no clinical symptoms before ICS reduction ≥24 months 89.50
AChPC20 >10 mg/mL + time with no clinical symptoms before ICS reduction ≥12 months 73.50
AChPC20 >10 mg/mL + time with no clinical symptoms before ICS reduction ≥24 months 81.00
AChPC20 >10 mg/mL + FeNO <40 ppb 75.90
AChPC20 >10 mg/mL + FeNO <30 ppb 78.60
AChPC20 >10 mg/mL + %FEV1 at ICS reduction >80 71.20
AChPC20 >10 mg/mL + %FEV1 at ICS reduction >90 70.30
AChPC20 >10 mg/mL + %FEV1 at ICS reduction >100 77.80
Time with no clinical symptoms before ICS reduction ≥12 months 64.10
Time with no clinical symptoms before ICS reduction ≥24 months 73.90
6.9 for patients with, exacerbations. However, in both
groups, the range for the time to exhibit clinical
symptoms was large (6 to 36 months) (Table 1).
The duration from onset of asthma to initiation of
ICS therapy, the kind of ICS, the daily dose of ICS,
and the duration of ICS therapy did not differ signifi-
cantly between the two groups. In addition, there
were no significant differences between the patient
groups in the use of other treatments such as LABA,
LTRA, long-acting muscarine antagonist (LAMA),
and theophylline (Table 2).
We used a multivariate logistic regression model to
determine factors predictive of a lack of exacerba-
tions after ICS reduction. Factors measured at the
time of ICS reduction that were most predictive of
success were, in order of significance: AChPC20 (p <
0.01), duration before ICS reduction without clinical
symptoms (p < 0.01), FeNO (p = 0.028), and %FEV1
(p = 0.03) (Table 3). The daily dose of ICS before re-
ducing ICS, the %V50, and the HistPC20 measured
when the ICS dose was reduced, were not predictive.
As described above, normalized AChPC20 >20 mg
mL at the time of ICS reduction was the best predic-
tor of an exacerbation-free period over the next 12
months (Table 3). The length of time for which pa-
tients were free of asthma symptoms before ICS re-
duction was the second most effective predictor. For
patients with normalized AChPC20 of >20 mgmL or >
10 mgmL andor an asthma-free period of at least 12
or 24 months before ICS reduction, we also com-
pared the percentages without any exacerbations
within 1 year after ICS reduction (Table 4). For pa-
tients with AChPC20 >20 mgmL, the percentage
without exacerbations within 1 year of ICS reduction
was 75.0%. Among those patients with AChPC20 >20
mgmL and no clinical symptoms for 12 or more
Tsurikisawa N et al.
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Fig.　5　Clinical courses of patients who continued on the same reduced dose of 
ICS, were given a further reduction in the dose of ICS, or discontinued ICS. Ka-
plan-Meier plot of the percentages of patients remaining free of exacerbations. 
Some patients did not experience exacerbations within 12 months of their initial 
ICS reduction. Twenty-one of these exacerbation-free patients continued on with 
their same reduced ICS dose (A). Eighteen continued at an ICS dose that was 
one-quarter their original dose (B), and 11 patients continued with no ICS (C).
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months before ICS reduction, 86.2% remained free of
exacerbations for at least 1 year. Moreover, among
those patients with AChPC20 >20 mgmL and no clini-
cal symptoms for 24 or more months before ICS re-
duction, 89.5% were exacerbation-free at 1 year (Ta-
ble 4). For patients with AChPC20 >10 mgmL at ICS
reduction and with no clinical symptoms for 24 or
more months before ICS reduction, 81.0% were
exacerbation-free. No other clinical factors or combi-
nation of factors identified any groups of patients that
achieved exacerbation-free percentages of greater
than 80%.
STUDY 2: We also analyzed the prognosis of 50 pa-
tients from Study 1 who had maintained total asthma
control for 12 months after ICS reduction (Fig. 1).
Twenty-one of the 50 patients continued therapy be-
yond 12 months at their half doses of ICS. Twenty of
these 21 patients remained exacerbation-free for a
mean of 21.5 ± 3.1 months after ICS reduction (Fig.
5). The asthma of 14 of the 18 patients (77.8%) with
severe asthma who had been treated with a maxi-
mum ICS daily dose of 1600 μg (as chlorofluorocar-
bon beclometasone dipropionate [CFC-BDP] equiva-
lent) before the first ICS reduction remained con-
trolled for a mean of 11.1 ± 1.6 months after a further
dose reduction to a quarter their original daily dose.
However, of the 11 patients with moderate asthma
who had used an initial daily ICS dose of 800 μg (as
CFC-BDP equivalent) before dose reduction to 400
μg and eventually discontinued their ICS entirely, 6
(54.5%) deteriorated at a mean of 4.2 ± 3.6 months af-
ter ICS discontinuation (Fig. 5). Thirty-nine of the 50
patients maintained total asthma control for at least 2
years after the initial ICS reduction.
DISCUSSION
It remains difficult to reduce inhaled ICS without pro-
moting subsequent exacerbations, even in adult
asthma patients who have achieved normalized BHRs
in response to ACh and who have not had asthma
symptoms for 6 months.21 Indeed, our results showed
that 44.4% of asthma patients with no clinical symp-
toms for at least 6 months experienced exacerbations
within 1 year after ICS reduction to half the initial
daily dose. These findings were independent of the
season at ICS reduction. Similarly, reduction of in-
haled ICS in patients with their asthma stabilized by
intermittent treatment with a combination of ICS and
LABA decreases the maximum mid forced expiratory
flow after 4 years.27 There are no published random-
ized controlled trials of step-down therapy of ICS,28
and guidelines for the rate of ICS reduction and the
interval for evaluation have not been validated. Given
the issues described above, and because asthma con-
trol may deteriorate at a highly variable rate and in-
tensity, we suggest that reduction of ICS therapy
should be gradual. This suggestion is reinforced by
our finding that patients in whom the duration of the
period without any clinical symptoms before ICS re-
duction was at least 24 months did not experience ex-
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acerbations compared with those in whom the
symptom-free period was at least 12 months.
Chronic eosinophilic inflammation in the lower air-
ways may promote airway remodeling.29-33 Airway re-
modeling is also influenced by the duration and se-
verity of asthma34-36 and by levels of serum IgE.37
Measures of lung function in asthma, including
BHR,38 small airway impairment1 measured as FEV1,
and V50, as well as markers of airway inflammation
such as eosinophils in sputum39 and FeNO,40 are use-
ful for monitoring asthma control. Moreover, BHR
and airflow limitations interact and are important risk
factors for the development of asthma. We reported
previously that, in adult patients with severe asthma,
BHR induced by ACh is related to the degree of
eosinophilic airway inflammation.36,41 However, BHR
induced by Hist indicates airway remodeling, and par-
ticularly airway smooth muscle hypertrophy.36,42 Pa-
tients in the group that experienced exacerbations af-
ter ICS reduction had a lower initial HistPC20 than pa-
tients that remained exacerbation-free. These results
may reflect greater airway remodeling in the group
that had subsequent exacerbations. However, by a
multivariate logistic regression model, AChPC20, but
not HistPC20, was the best predictive factor. This re-
sult may indicate that patients with less eosinophilic
airway inflammation can be treated successfully with
ICS reduction and remain exacerbation free for an ex-
tended time, even if they have some airway remodel-
ing, such as airway smooth muscle hypertrophy.
Our results showed that the most predictive factors
of success in stepping down ICS without subsequent
exacerbations were, first, normalized BHR induced
by ACh, and second, a history, before ICS reduction,
of 24 or more months that were free of asthma symp-
toms. In addition to AChPC20, we evaluated FeNO
and FEV1 as potential predictors of success of ICS re-
duction. In this study, 26 of 90 patients (28.9%) were
ex- or current smokers. We previously reported a
higher cutoff point of FeNO in smokers with asthma
than in non-smokers.43 Our data showed that FeNO
at the time of ICS reduction was significantly lower in
the exacerbation-free group, independent of whether
patients were current or ex-smokers. Thus the differ-
ence in FeNO may not reflect the effects of smoking.
Our analysis of the initial characteristics of patients
who had no exacerbations for at least 12 months after
ICS reduction (Table 3) suggested specific factors
that could be clinically useful in identifying patients
likely to respond well to ICS reduction. The most im-
portant factor is normalized AChPC20 alone, or in ad-
dition to a symptom-free period of 12 or 24 months
before ICS reduction. Patients with AChPC20 10
mgmL and free of any clinical symptoms for at least
24 months before ICS reduction also appeared to
have fewer exacerbations in the 12-month study pe-
riod. However, other patient characteristics such as
FEV1 or FeNO before ICS reduction combined with
AChPC20 10 mgmL did not define groups with
comparable percentages of exacerbation-free patients
(Table 3). A symptom-free period of at least 12 or 24
months before ICS reduction was in itself not a pre-
dictor of a 12-month exacerbation-free period after re-
duction.
We analyzed further the prognosis of 50 patients in
Study 1 who had maintained total asthma control for
12 months after ICS reduction. Thirty-nine of these
patients maintained total asthma control for at least 2
years after their initial ICS reduction. However, most
exacerbations in Study 2 patients occurred within 12
months in the group that discontinued all ICS treat-
ment after their initial ICS reduction.
The predictive factors that we identified may be
useful in defining asthma patients who would benefit
for an extended period of time from ICS reduction.
However, the complexities of the clinical response to
ICS reduction, as illustrated above, indicate that re-
mission or cure of adult asthma remains difficult and
warrants further study.
GINA1 and Japanese44 Guidelines recommend
treatment protocols to achieve asthma control that
are based on a patient’s level of asthma control. How-
ever, ICS reduction soon after achieving initial con-
trol can lead to asthma exacerbations, and repetitive
exacerbations may lead to airway remodeling34,35 or
decreased FEV1.45 In light of the findings reported
here, we recommend that step-down therapy should
be performed gradually after patients have been
symptom-free for at least 24 months. As a result, the
low frequency of exacerbations may suppress airway
remodeling, give a good prognosis, and contribute to
reduced long-term medical expenses.
In summary, we demonstrated useful factors, such
as AChPC20, for identifying patients who could re-
main exacerbation-free for extended periods of time
with a reduction in their daily ICS dose. However, the
ability to test for AChPC20 is not always available in
hospitals and clinics. It would therefore be worth-
while in future studies to examine the use of simpler
tools, such as peak expiratory flow or questionnaires,
that are widely used in general practice.
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